SCHEMBL4890693

SCHEMBL4890693

c1coc(-c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.68
MAPT P10636 6/20 0.67
MAPK1 P28482 3/20 0.67
AHR P35869 1/20 0.67
HTT P42858 1/20 0.67
TTBK1 Q5TCY1 2/20 0.52
TTBK2 Q6IQ55 2/20 0.52
POLB P06746 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
MAPKAPK2 P49137 1/20 0.51
CLK4 Q9HAZ1 6/20 0.49
DYRK1A Q13627 1/20 0.49
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 3/20 0.47
TSHR P16473 3/20 0.47
USP2 O75604 3/20 0.47
LMNA P02545 2/20 0.47
HSD17B10 Q99714 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008515 0.88 MAPT (0.80) PI4KBMAPTMAPK1AHRHTT
SCHEMBL14026142 0.85 MAPK1 (0.72) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4007152 0.83 MAPK1 (0.72) PI4KBMAPTMAPK1AHRHTT
SCHEMBL29360509 0.81 PI4KB (1.00) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4890645 0.81 PI4KB (1.00) PI4KBMAPTMAPK1AHRHTT
SCHEMBL1824352 0.81 CLK4 (0.49) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4889115 0.81 MAPT (0.66) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4891700 0.81 CLK4 (0.67) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4890642 0.81 PI4KB (0.72) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4884754 0.81 PI4KB (0.81) PI4KBMAPTMAPK1AHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 PI4KB 739/4885MAPT 2064/4885MAPK1 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.